Estradioldosage

Generally, when estrogen is prescribed for a postmenopausal woman with a uterus, consider addition of a progestogen to reduce the risk of endometrial cancer. Generally, a woman without a uterus does not need to use a progestogen in addition to her estrogen therapy. In some cases, however, hysterectomized women who have a history of endometriosis may need a progestogen. Use estrogen-alone, or in combination with a progestogen, at the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Re-evaluate postmenopausal women periodically as clinically appropriate to determine whether treatment is still necessary.

Start therapy with one spray of Evamist once daily each morning to forearm

Dosage adjustment to two or three sprays of Evamist should be guided by the clinical response

2.1 Treatment of

Moderate to Severe Vasomotor Symptoms due to Menopause Start Evamist therapy with one spray of Evamist per day. Make dosage adjustment based on the clinical response. Prime the Evamist container by spraying 5 sprays with the cover on before applying the first dose from a new applicator. Hold the container upright and vertical for spraying. Apply one, two or three sprays each morning to adjacent, non-overlapping areas on the inner surface of the forearm, starting near the elbow. Allow the sprays to dry for approximately 2 minutes before covering the site with clothing. Do not wash the application site for at least one hour. Application of Evamist to other skin surfaces has not been adequately studied. Evamist should not be applied to skin surfaces other than the forearm. Strict adherence to the following precautions is advised in order to minimize the potential for secondary exposure to estradiol from Evamist-treated skin. Cover the Evamist application site with clothing if another person may come into contact with that area of skin after the spray dries. Additional precautions to minimize unintentional secondary exposure are outlined in Patient Counseling Information and in the Patient Information Leaflet at the end of the prescribing information.